ClinicalTrials.gov
ClinicalTrials.gov Menu

Performance of a New Glucose Meter System in Children and Young Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00985257
Recruitment Status : Completed
First Posted : September 28, 2009
Results First Posted : November 2, 2010
Last Update Posted : February 29, 2016
Sponsor:
Information provided by (Responsible Party):
Ascensia Diabetes Care

Brief Summary:
The purpose of this study is to evaluate the performance of a new blood glucose meter in the hands of children, teens, young adults.

Condition or disease Intervention/treatment Phase
Diabetes Device: DIDGET (Investigational Blood Glucose Monitoring System) Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Performance of the DIDGET Blood Glucose Monitoring System in Children and Young Adults
Study Start Date : September 2009
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Sugar
Drug Information available for: Dextrose
U.S. FDA Resources

Arm Intervention/treatment
Subjects with diabetes
Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
Device: DIDGET (Investigational Blood Glucose Monitoring System)
Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.



Primary Outcome Measures :
  1. Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method [ Time Frame: 1-2 hours ]
    Subjects with diabetes and healthcare professionals (HCPs) used a new blood glucose monitoring system (BGMS) with subject blood. BGM results were compared to a lab glucose method - Yellow Springs Instrument (YSI) Analyzer. Duplicate BG results were used to calculate the number of BG results within +/-15mg/dL (for reference BG results <75mg/dL) or +/- 20% (for reference BG values >/=75mg/dL) of the reference method results.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 or Type 2 diabetes
  • Age 4 to 24 years
  • Routinely performs blood glucose testing at home
  • If age 18 or older at time informed consent is signed, subject must be able to speak, read, and understand English.
  • If younger than age 18, subject's parent/guardian must be able to speak, read, and understand English, and is able to provide appropriate supervision.
  • Is willing to complete all study procedures, with or without parent / guardian supervision, if appropriate

Exclusion Criteria:

  • Currently pregnant
  • Hemophilia or any other bleeding disorder
  • Taking prescription anticoagulants (such as Warfarin or heparin) or has clotting problems that may prolong bleeding. Taking Plavix or aspirin daily is not excluded
  • Infection with a blood borne pathogen (e.g., HIV, hepatitis)
  • Subject or parent/guardian is employee of competitive medical device company
  • Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00985257


Locations
United States, California
AMCR Institute
Escondido, California, United States, 92026
United States, Florida
Larry C. Deeb, MD PA
Tallahassee, Florida, United States, 32308
Sponsors and Collaborators
Ascensia Diabetes Care
Investigators
Principal Investigator: Timothy Bailey, MD AMCR Institute
Principal Investigator: Larry C Deeb, MD PA Larry C. Deeb, MD PA

Responsible Party: Ascensia Diabetes Care
ClinicalTrials.gov Identifier: NCT00985257     History of Changes
Other Study ID Numbers: CTD-2009-35
First Posted: September 28, 2009    Key Record Dates
Results First Posted: November 2, 2010
Last Update Posted: February 29, 2016
Last Verified: January 2016